26646-35-5 Usage
Uses
Used in Scientific Research:
2-(3-Nitrophenoxy)ethylamine is used as a research compound for its ability to participate in various chemical reactions. Its presence in scientific research is primarily due to its reactivity and the potential for further exploration of its chemical properties and behavior.
Used in Industrial Applications:
In the industrial sector, 2-(3-Nitrophenoxy)ethylamine is used as an intermediate compound in the synthesis of other chemicals. Its functional groups and reactivity make it a valuable component in the production of a variety of chemical products, contributing to the development of new materials and compounds.
Used in Chemical Synthesis:
2-(3-Nitrophenoxy)ethylamine is used as a synthetic building block for the creation of more complex molecules. Its versatility in chemical reactions allows it to be a key component in the synthesis of a wide array of chemical entities, facilitating advancements in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 26646-35-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,6,4 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 26646-35:
(7*2)+(6*6)+(5*6)+(4*4)+(3*6)+(2*3)+(1*5)=125
125 % 10 = 5
So 26646-35-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H10N2O3/c9-4-5-13-8-3-1-2-7(6-8)10(11)12/h1-3,6H,4-5,9H2
26646-35-5Relevant academic research and scientific papers
Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents
Wu, Zhaoyang,Lu, Yu,Li, Linhu,Zhao, Rui,Wang, Bin,Lv, Kai,Liu, Mingliang,You, Xuefu
, p. 1130 - 1133 (2016/12/16)
A series of imidazo[1,2-a]pyridine carboxamides (IPAs) bearing an N-(2-phenoxyethyl) moiety was designed and synthesized as new antitubercular agents. Seven 2,6-dimethyl IPAs demonstrated excellent in vitro activity (MIC: 0.025-0.054 μg/mL) against the drug susceptive H37Rv strain and two clinically isolated multidrug-resistant Mycobacterium tuberculosisstrains. Compound 10j displayed acceptable safety and pharmacokinetic properties, opening a new direction for further development.
